论文部分内容阅读
7例严重早产儿肺透明膜病（HMD）用肺表面活性物质（curosurf）替代疗法，给予Curosurf的标准包括机械通气所需之FiO2≥0．6及动脉氧分压／肺泡氧分压（a／APO2）≤0．1，7例在年龄5～48小时给单剂Curosurf（200mg／kg）治疗，给药30分钟后7例的氧合均迅速改善，a／APO2及PaO2／FiO2各增加了2．5～4．7倍及2．5～4．4倍，无气漏并发，6例存活，1例死于医院内感染，Curosurf治疗有效的改善严重HMD的转归及减低气漏的发生率
Seven patients with severe preterm infants with hyaline membrane disease (HMD) were treated with curosurf replacement therapy. Curosurf criteria were included for FiO2 ≥ 0.6 required for mechanical ventilation and arterial partial pressure of oxygen / alveolar oxygen pressure (a /APO2)≤0.1,7,7 patients were treated with single dose of Curosurf (200mg / kg) at the age of 5-48hours. After 30mins administration, the oxygenation of 7 patients improved rapidly and a / APO2 and PaO2 / FiO2 increased 2.5 to 4.7 times and 2.5 to 4.4 times, no air leakage concurrent, 6 cases survived, 1 case died of nosocomial infection, Curosurf treatment is effective in improving the outcome of severe HMD and reduce air leakage The incidence of